Christopher J Hostler, Jay Krishnan, Alice Parish, Allison Baroco, Penny Cooper, Onofre Donceras, Ebbing Lautenbach, Pam Tolomeo, Tracy Sansossio, Carlos A Q Santos, David Schwartz, Helen Zhang, Sharon Welbel, Yuliya Lokhnygina, Deverick J Anderson
{"title":"结肠手术接受厄他培南抗菌药预防后的术后效果:一项多中心回顾性队列研究。","authors":"Christopher J Hostler, Jay Krishnan, Alice Parish, Allison Baroco, Penny Cooper, Onofre Donceras, Ebbing Lautenbach, Pam Tolomeo, Tracy Sansossio, Carlos A Q Santos, David Schwartz, Helen Zhang, Sharon Welbel, Yuliya Lokhnygina, Deverick J Anderson","doi":"10.1017/ice.2024.99","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate postoperative outcomes among patients undergoing colon surgery who receive perioperative prophylaxis with ertapenem compared to other antibiotic regimens.</p><p><strong>Design and setting: </strong>Multicenter retrospective cohort study among adults undergoing colon surgery in seven hospitals across three health systems from 1/1/2010 to 9/1/2015.</p><p><strong>Methods: </strong>Generalized linear mixed logistic regression models were applied to assess differential odds of select outcomes among patients who received perioperative prophylaxis with ertapenem compared to other regimens. Postoperative outcomes of interest included surgical site infection (SSI), <i>Clostridioides difficile</i> infection (CDI) and clinical culture positivity for carbapenem-resistant <i>Enterobacteraciae</i> (CRE). Inverse probability weights were applied to account for differing covariate distributions across ertapenem and non-ertapenem groups.</p><p><strong>Results: </strong>A total of 2,109 patients were included for analysis. The odds of postoperative SSI was 1.56 times higher among individuals who received ertapenem than among those receiving other perioperative antimicrobial prophylaxis regimens in our cohort (46 [3.5%] vs 20 [2.5%]; IPW-weighted OR 1.56, [95% CI, 1.08-2.26], <i>P</i> = .02). No statistically significant differences in odds of postoperative CDI (24 [1.8%] vs 16 [2.0%]; IPW-weighted OR 1.07 [95% CI, .68-1.68], <i>P</i> = .78) were observed between patients who received ertapenem prophylaxis compared to other regimens. Clinical CRE culture positivity was rare in both groups (.2%-.5%) and did not differ statistically.</p><p><strong>Conclusions: </strong>Ertapenem use for perioperative prophylaxis was associated with increased odds of SSI among patients undergoing colon surgery in our study population, though no differences in CDI or clinical CRE culture positivity were identified. Further study and replication of these findings are needed.</p>","PeriodicalId":13663,"journal":{"name":"Infection Control and Hospital Epidemiology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611502/pdf/","citationCount":"0","resultStr":"{\"title\":\"Postoperative outcomes after receipt of ertapenem antimicrobial prophylaxis for colon surgery: a multicenter retrospective cohort study.\",\"authors\":\"Christopher J Hostler, Jay Krishnan, Alice Parish, Allison Baroco, Penny Cooper, Onofre Donceras, Ebbing Lautenbach, Pam Tolomeo, Tracy Sansossio, Carlos A Q Santos, David Schwartz, Helen Zhang, Sharon Welbel, Yuliya Lokhnygina, Deverick J Anderson\",\"doi\":\"10.1017/ice.2024.99\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate postoperative outcomes among patients undergoing colon surgery who receive perioperative prophylaxis with ertapenem compared to other antibiotic regimens.</p><p><strong>Design and setting: </strong>Multicenter retrospective cohort study among adults undergoing colon surgery in seven hospitals across three health systems from 1/1/2010 to 9/1/2015.</p><p><strong>Methods: </strong>Generalized linear mixed logistic regression models were applied to assess differential odds of select outcomes among patients who received perioperative prophylaxis with ertapenem compared to other regimens. Postoperative outcomes of interest included surgical site infection (SSI), <i>Clostridioides difficile</i> infection (CDI) and clinical culture positivity for carbapenem-resistant <i>Enterobacteraciae</i> (CRE). Inverse probability weights were applied to account for differing covariate distributions across ertapenem and non-ertapenem groups.</p><p><strong>Results: </strong>A total of 2,109 patients were included for analysis. The odds of postoperative SSI was 1.56 times higher among individuals who received ertapenem than among those receiving other perioperative antimicrobial prophylaxis regimens in our cohort (46 [3.5%] vs 20 [2.5%]; IPW-weighted OR 1.56, [95% CI, 1.08-2.26], <i>P</i> = .02). No statistically significant differences in odds of postoperative CDI (24 [1.8%] vs 16 [2.0%]; IPW-weighted OR 1.07 [95% CI, .68-1.68], <i>P</i> = .78) were observed between patients who received ertapenem prophylaxis compared to other regimens. Clinical CRE culture positivity was rare in both groups (.2%-.5%) and did not differ statistically.</p><p><strong>Conclusions: </strong>Ertapenem use for perioperative prophylaxis was associated with increased odds of SSI among patients undergoing colon surgery in our study population, though no differences in CDI or clinical CRE culture positivity were identified. Further study and replication of these findings are needed.</p>\",\"PeriodicalId\":13663,\"journal\":{\"name\":\"Infection Control and Hospital Epidemiology\",\"volume\":\" \",\"pages\":\"1-6\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611502/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection Control and Hospital Epidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/ice.2024.99\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection Control and Hospital Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/ice.2024.99","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
目的评估与其他抗生素方案相比,接受厄他培南围手术期预防的结肠手术患者的术后效果:多中心回顾性队列研究:2010年1月1日至2015年1月9日期间,在三个医疗系统的七家医院接受结肠手术的成人:方法:应用广义线性混合逻辑回归模型评估围手术期接受厄他培南预防治疗的患者与其他治疗方案的患者发生特定结果的不同几率。术后相关结果包括手术部位感染(SSI)、艰难梭菌感染(CDI)和耐碳青霉烯类肠杆菌(CRE)临床培养阳性。为了考虑厄他培南组和非厄他培南组之间不同的协变量分布,采用了反概率加权:共纳入 2,109 例患者进行分析。在我们的队列中,接受厄他培南治疗的患者术后发生 SSI 的几率是接受其他围手术期抗菌药物预防方案患者的 1.56 倍(46 [3.5%] vs 20 [2.5%];IPW 加权 OR 1.56,[95% CI,1.08-2.26],P = .02)。与其他方案相比,接受厄他培南预防方案的患者术后感染 CDI 的几率(24 [1.8%] vs 16 [2.0%];IPW 加权 OR 1.07 [95% CI, .68-1.68], P = .78)无统计学差异。临床 CRE 培养阳性率在两组中都很少见(.2%-.5%),且无统计学差异:结论:在我们的研究人群中,使用厄他培南进行围手术期预防与接受结肠手术的患者发生 SSI 的几率增加有关,尽管在 CDI 或临床 CRE 培养阳性率方面没有发现差异。这些发现需要进一步研究和验证。
Postoperative outcomes after receipt of ertapenem antimicrobial prophylaxis for colon surgery: a multicenter retrospective cohort study.
Objective: To evaluate postoperative outcomes among patients undergoing colon surgery who receive perioperative prophylaxis with ertapenem compared to other antibiotic regimens.
Design and setting: Multicenter retrospective cohort study among adults undergoing colon surgery in seven hospitals across three health systems from 1/1/2010 to 9/1/2015.
Methods: Generalized linear mixed logistic regression models were applied to assess differential odds of select outcomes among patients who received perioperative prophylaxis with ertapenem compared to other regimens. Postoperative outcomes of interest included surgical site infection (SSI), Clostridioides difficile infection (CDI) and clinical culture positivity for carbapenem-resistant Enterobacteraciae (CRE). Inverse probability weights were applied to account for differing covariate distributions across ertapenem and non-ertapenem groups.
Results: A total of 2,109 patients were included for analysis. The odds of postoperative SSI was 1.56 times higher among individuals who received ertapenem than among those receiving other perioperative antimicrobial prophylaxis regimens in our cohort (46 [3.5%] vs 20 [2.5%]; IPW-weighted OR 1.56, [95% CI, 1.08-2.26], P = .02). No statistically significant differences in odds of postoperative CDI (24 [1.8%] vs 16 [2.0%]; IPW-weighted OR 1.07 [95% CI, .68-1.68], P = .78) were observed between patients who received ertapenem prophylaxis compared to other regimens. Clinical CRE culture positivity was rare in both groups (.2%-.5%) and did not differ statistically.
Conclusions: Ertapenem use for perioperative prophylaxis was associated with increased odds of SSI among patients undergoing colon surgery in our study population, though no differences in CDI or clinical CRE culture positivity were identified. Further study and replication of these findings are needed.
期刊介绍:
Infection Control and Hospital Epidemiology provides original, peer-reviewed scientific articles for anyone involved with an infection control or epidemiology program in a hospital or healthcare facility. Written by infection control practitioners and epidemiologists and guided by an editorial board composed of the nation''s leaders in the field, ICHE provides a critical forum for this vital information.